Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_151_библиотеки_им_акад_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
10 Мб
Скачать
☆
318 A. Sudlow et al.
https://t.me/med1917
of dumping syndrome in food avoidance and subsequent weight loss, management of symptoms is an important clinical target.
9.7 Psychological Factors
Adjusting to postoperative dietary recommendations can be difficult after a life­changing event, such as surgery. The surgery may cause food aversion and unhealthy food behaviors due to unpleasant symptoms experienced with certain foods, which can result in a reluctance to retry these foods at a later stage. Contro­versy remains about whether the changes in behavior are entirely because of food aversion or whether more likely to be due to food avoidance. Food aversions are described as occurring when an individual comes to associate an unpleasant effect, i.e., nausea, with a specific taste or food, resulting in a strong dislike and resistance to ingestion. Conversely in the case of food avoidance, although the individual may still feel a specific food is enjoyable, they will attempt to reduce their intake in the knowledge they may develop symptoms following ingestion (Al-Najim et al. 2018). It is thought that nearly 50% of patients have concerns about food aversions in the postoperative period following esophagectomy, which may contribute to dietary limitations and weight loss (Schandl et al. 2020).
In addition, there can be resistance from patients to adjust their expectations following surgery, and ongoing difficulties and changes in dietary habits may be exacerbated by disillusion as to what the new “normal” for the patient has become. Qualitative studies have described “fear” of eating owing to an inability to eat normal-sized meals or secondary to unpleasant GI symptoms following ingestion, which results in emotional and psychological distress (Ginex et al. 2013; Greene et al. 2014 ; Haverkort et al. 2010).
Emotional and psychological distress at mealtimes results in isolation in relation to eating, and while eating serves an important physiological purpose, it has signifi­cant social importance within our modern society and cultures. This is often compounded by healthcare professionals adopting a patriarchal approach and instructing patients how to eat when the patient is not able to adhere to the instructions because of physiological changes after the esophagectomy.
9.8 Micronutrient Deficiencies
Suboptimal intakes of folic acid, vitami n D, copper, calcium, zinc, and vitamin B1 are frequently seen in the postoperative period (Haverkort et al. 2012). Nearly 90% of patients have been shown to have inadequate micronutrient levels 18 months following surgery with nearly 50% being iron deficient (Heneghan et al. 2015). To date, there are no robust guidelines to inform clinicians and dietitians on standardized protocols for long-term monitoring, and practices vary widely between units.
Unintentional Weight Loss and Malnutrition After Esophageal Cancer and Treatment 319
https://t.me/med1917
10 Nutritional Support Following Esophagectomy
Nutritional support in patients following esophagectomy is recognized as an impor­tant element in postoperative recovery given the invasiveness of the procedure and the high likelihood of subsequent weight loss. This is of particular concern consid­ering the potential implications for weight maintenance in a population that may be suffering from nutritional deficiencies at baseline and its implications for outcomes. Although there is variation in terms of the timing, route, and delivery of supplemen­tal nutrition, evidence from several enhanced recovery pathway protocols supports the importance of including elements of enhanced recovery after surgery (ERAS) pathways related to an early oral diet. Several studies looking at ERAS pathways have found that early oral feeding following esophagectomy is safe and associated with decreased hospital length of stay (LOS), return of normal bowel function, and short-term improvement in quality of life without any increase in complications (Mahmoodzadeh et al. 2015; Sun et al. 2018). Until recently, there had been ambiguity regarding the impact of early oral intake on the risk of anastomotic leak. However, the multicenter RCT, Direct Oral Feeding Following Minimally Invasive Esophagectomy (NUTRIENT II) trial, demonstrated no significant differ­ence in the leak rate or other complications in those commencing immediate oral diet compared to those kept nil by mouth until day 5 postoperatively following mini­mally invasive esophagectomy (Berkelmans et al. 2020). It also found that a direct oral diet had a positive effect on functional recovery. The impact of early diet may depend in part on the surgical approach as well as additional factors, and as such, many units continue to advocate for a period of highly restricted oral intake as the exact timing for the initiation of oral intake is unclear, necessitating the delivery of supplemental nutrition. In this context or as an adjunct to support early oral diet, enteral feeding via either jejunostomy or nasojejunal feeding tube is widely accepted as the standard of care, contributing to the preservation of the gut barrier while associated with a lower risk of postoperative complications compared to parenteral nutrition (Findlay et al. 2014). Although the practice is somewhat variable and there is no clear evidence to support the superiority of either method, the most common route of delivery is via the placement of a jejunal feeding tube placed intraoperatively. A 2020 survey within the United Kingdom report ed that more than half of all units routinely placed feeding jejunostomy tubes in patients undergoing esophagectomy (Tham et al. 2020). In spite of the apparent benefits of early oral nutrition, several studies have demonstrated that many patients are unable to main­tain adequate caloric intake in the early postoperative period. A multicenter trial demonstrated that patients on an oral diet alone were only able to meet 60% of their daily caloric intake following esophagectomy, further supporting the view that supplemental enteral nutrition is required (Weijs et al. 2016). The benefits of delivering early enteral feeding via jejunostomy are supported by several studies including the analysis of the Surveillance, Epidemiology, and End Results (SEER) database of nearly 2500 patients undergoing esophagectomy, demonstrating lower 90-day mortality and short er hospital LOS in those with a jejunostomy compared to those without of (Lorimer et al. 2019).
320 A. Sudlow et al.
https://t.me/med1917
Although the concept of providing a period of prolonged enteral feeding has been considered a potential treatment to prevent or reduce postoperative weight loss, evidence at present does not support its widespread use. A 2015 study looking at the use of routine feeding via gastrojejunostomy found weight could be maintained during a prolonged period of supplemental feeding. However, patients subsequently lost weight once supplemental feeding was stopped, irrespective of the time interval following esophagectomy. The use of a feeding jejunostomy did not improve LOS or readmissions (Weijs et al. 2017). Further calling into question this approach, a prospective cohort study found that despite near-complete compliance with an enteral feeding regimen started on day 1 following esophagectomy via feeding jejunostomy for 4 months, more than 40% of patients lost >10% weight over a 6-month follow-up period (Donohoe et al. 2017). Although the routine use of prolonged enteral feeding is not supported, it may be employed on a case-by-case basis to mitigate or manage postoperative complications such as anastomotic leak where oral intake is prohibited for an extended period or in those who are failing to meet their caloric needs via the oral route.
11 Conclusion
The method of managing unintentional weight loss in patients following esophagectomy is highly dependent on a number of factors, including baseline function, comorbidities, surgical techniques, and the presence of postoperative complications. Although this helps inform the approach to managing patients in this context, it is important to be mindful that unintentional weight loss is in itself the result of the combination of the physiological processes driven by the condition and its treatment as well as psychological factors, requiring a patient-centered approach to long-term management. Further insight into the mechanical changes resulting from the anatomical resection of the esophagus and reconstruction, as well as those mediated by gut hormones, is required. The development of pharmacological interventions which may help counteract some of the physiological changes mediated by esophagectomy, particularly those related to gut hormones, may play a key role in developing strategies to help treat or mitigate some of the weight loss which often negatively impacts patients’ long-term recovery and quality of life.
References
(2019) Surveillance Epidemiology and End Results (SEER) Program (2020) Esophagus Cancer Early Detection, Diagnosis, and Staging [Online]. Available: https://
www.cancer.org/cancer/esophagus-cancer/detection-diagnosis-staging/signs-and-symptoms.
html. Accessed November 20, 2021
Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag
GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S,
Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM,
Unintentional Weight Loss and Malnutrition After Esophageal Cancer and Treatment 321
https://t.me/med1917
Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M,
Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G,
Rethwisch V, Von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J,
Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S,
Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD, Investigators F-A (2019) Perioper-
ative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluoro-
uracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or
gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet
393:1948–1957 Al-Najim W, Docherty NG, Le Roux CW (2018) Food intake and eating behavior after bariatric
surgery. Physiol Rev 98:1113–1141 Allum W, Lordick F, Alsina M, Andritsch E, Ba-Ssalamah A, Beishon M, Braga M, Caballero C,
Carneiro F, Cassinello F, Dekker JW, Delgado-Bolton R, Haustermans K, Henning G, Hutter B,
Lövey J, Netíková I, Obermannová R, Oberst S, Rostoft S, Saarto T, Seufferlein T, Sheth S,
Wynter-Blyth V, Costa A, Naredi P (2018) ECCO essential requirements for quality
cancer care: oesophageal and gastric cancer. Crit Rev Oncol Hematol 122:179–193 Anandavadivelan P, Lagergren P (2016) Cachexia in patients with oesophageal cancer. Nat Rev
Clin Oncol 13:185–198 Arts J, Caenepeel P, Bisschops R, Dewulf D, Holvoet L, Piessevaux H, Bourgeois S, Sifrim D,
Janssens J, Tack J (2009) Efficacy of the long-acting repeatable formulation of the somatostatin
analogue octreotide in postoperative dumping. Clin Gastroenterol Hepatol 7:432–437 Baker M, Halliday V, Williams RN, Bowrey DJ (2016) A systematic review of the nutritional
consequences of esophagectomy. Clin Nutr 35:987–994 Baker ML, Halliday V, Robinson P, Smith K, Bowrey DJ (2017) Nutrient intake and contribution of
home enteral nutrition to meeting nutritional requirements after oesophagectomy and total
gastrectomy. Eur J Clin Nutr 71:1121–1128 Berkelmans GHK, Fransen LFC, Dolmans-Zwartjes ACP, Kouwenhoven EA, Van Det MJ,
Nilsson M, Nieuwenhuijzen GAP, Luyer MDP (2020) Direct oral feeding following minimally
invasive esophagectomy (NUTRIENT II trial): an international, multicenter, open-label
randomized controlled trial. Ann Surg 271:41–47 Carmody JS, Muñoz R, Yin H, Kaplan LM (2016) Peripheral, but not central, GLP-1 receptor
signaling is require d for improvement in glucose tolerance after Roux-en-Y gastric bypass in
mice. Am J Physiol Endocrinol Metab 310:E855–E861 Cunningham D, Allum WH, Stenning SP, Thompson JN, Van De Velde CJ, Nicolson M, Scarffe
JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Magic
Trial Participants (2006) Perioperative chemotherapy versus surgery alone for resectable gas-
troesophageal cancer. N Engl J Med 355:11–20 De Silva A, Bloom SR (2012) Gut hormones and appetite control: a focus on PYY and GLP-1 as
therapeutic targets in obesity. Gut Liver 6:10–20 Doki Y, Takachi K, Ishikawa O, Miyashiro I, Sasaki Y, Ohigashi H, Nakajima H, Hosoda H,
Kangawa K, Sasakuma F, Motoori M, Imaoka S (2006) Ghrelin reduction after esophageal
substitution and its correlation to postoperative body weight loss in esophageal cancer patients.
Surgery 139:797–805 Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á (2015) Esophageal cancer: risk factors,
screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol
21:7933–7943 Donington JS (2006) Functional conduit disorders after esophagectomy. Thorac Surg Clin
16:53–62 Donohoe CL, Healy LA, Fanning M, Doyle SL, Hugh AM, Moore J, Ravi N, Reynolds JV (2017)
Impact of supplemental home enteral feeding postesophagectomy on nutrition, body composi-
tion, quality of life, and patient satisfaction. Dis Esophagus 30:1–9 Elliott JA, Reynolds JV, Le Roux CW, Docherty NG (2016) Physiology, pathophysiology and
therapeutic implications of enteroendocrine control of food intake. Expert Rev Endocrinol
Metab 11:475–499
322 A. Sudlow et al.
https://t.me/med1917
Elliott JA, Docherty NG, Eckhardt HG, Doyle SL, Guinan EM, Ravi N, Reynolds JV, Roux CWL
(2017) Weight loss, satiety, and the postprandial gut hormone response after esophagectomy: a
prospective study. Ann Surg 266:82–90 Elliott J, Docherty N, Murphy C, Eckhardt HG, Doyle S, Guinan E, Ravi N, Reynolds J, Le Roux C
(2019a) Changes in gut hormones, glycaemic response and symptoms after oesophagectomy.
Br J Surg 106:735–746 Elliott JA, Docherty NG, Haag J, Eckhardt HG, Ravi N, Reynolds JV, Le Roux CW (2019b)
Attenuation of satiety gut hormones increases appetitive behavior after curative esophagectomy
for esophageal cancer. Am J Clin Nutr 109:335–344 Elliott JA, Docherty NG, Murphy CF, Eckhardt HG, Doyle SL, Guinan EM, Ravi N, Reynolds JV,
Le Roux CW (2019c) Changes in gut hormones, glycaemic response and symptoms after
oesophagectomy. Br J Surg 106:735–746 Findlay JM, Gillies RS, Millo J, Sgromo B, Marshall RE, Maynard ND (2014) Enhanced recovery
for esophagectomy: a systematic review and evidence-based guidelines. Ann Surg 259:413–431 Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Dore J,
Henegar C, Rizkalla S, Clement K (2010) Differential adaptation of human gut microbiota to
bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation
markers. Diabetes 59:3049–3057 Ginex P, Thom B, Jingeleski M, Vincent A, Plourde G, Rizk N, Rusch VW, Bains M (2013)
Patterns of symptoms following surgery for esophageal cancer. Oncol Nurs Forum 40:
E101–E107 Greene CL, Demeester SR, Worrell SG, Oh DS, Hagen JA, Demeester TR (2014) Alimentary
satisfaction, gastrointestinal symptoms, and quality of life 10 or more years after esophagectomy
with gastric pull-up. J Thorac Cardiovasc Surg 147:909–914 Guo Y, Huang ZP, Liu CQ, Qi L, Sheng Y, Zou DJ (2018) Modulation of the gut microbiome: a
systematic review of the effect of bariatric surgery. Eur J Endocrinol 178:43–56 Haverkort EB, Binnekade JM, Busch OR, Van Berge Henegouwen MI, De Haan RJ, Gouma DJ
(2010) Presence and persistence of nutrition-related symptoms during the first year following
esophagectomy with gastric tube reconstruction in clinically disease-free patients. World J Surg
34:2844–2852 Haverkort EB, Binnekade JM, De Haan RJ, Busch OR, Van Berge Henegouwen MI, Gouma DJ
(2012) Suboptimal intake of nutrients after esophagectomy with gastric tube reconstruction.
J Acad Nutr Diet 112:1080–1087 Heneghan HM, Zaborowski A, Fanning M, Mchugh A, Doyle S, Moore J, Ravi N, Reynolds JV
(2015) Prospective study of malabsorption and malnutrition after esophageal and gastric cancer
surgery. Ann Surg 262:803–807; discussion 807–8 Koizumi M, Hosoya Y, Dezaki K, Yada T, Hosoda H, Kangawa K, Nagai H, Lefor AT, Sata N,
Yasuda Y (2011) Postoperative weight loss does not resolve after esophagectomy despite
normal serum ghrelin levels. Ann Thorac Surg 91:1032–1037 Konradsson M, Nilsson M (2019) Delayed emptying of the gastric conduit after esophagectomy.
J Thorac Dis 11:S835–S844 Konradsson M, Van Berge Henegouwen MI, Bruns C, Chaudry MA, Cheong E, Cuesta MA,
Darling GE, Gisbertz SS, Griffin SM, Gutschow CA, Van Hillegersberg R, Hofstetter W,
Hölscher AH, Kitagawa Y, Van Lanschot JJB, Lindblad M, Ferri LE, Low DE, Luyer MDP,
Ndegwa N, Mercer S, Moorthy K, Morse CR, Nafteux P, Nieuwehuijzen GAP, Pattyn P,
Rosman C, Ruurda JP, Räsänen J, Schneider PM, Schröder W, Sgromo B, Van Veer H,
Wijnhoven BPL, Nilsson M (2020) Diagnostic criteria and symptom grading for delayed gastric
conduit emptying after esophagectomy for cancer: international expert consensus based on a
modified Delphi process. Dis Esophagus 33 Lagergren P, Avery KN, Hughes R, Barham CP, Alderson D, Falk SJ, Blazeby JM (2007) Health-
related quality of life among patients cured by surgery for esophageal cancer. Cancer 110:
686–693
Unintentional Weight Loss and Malnutrition After Esophageal Cancer and Treatment 323
https://t.me/med1917
Li JV, Ashrafian H, Bueter M, Kinross J, Sands C, Le Roux CW, Bloom SR, Darzi A,
Athanasiou T, Marchesi JR, Nicholson JK, Holmes E (2011) Metabolic surgery profoundly
influences gut microbial-host metabolic cross-talk. Gut 60:1214–1223 Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D, Committee EG (2016)
Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-
up. Ann Oncol 27:v50–v57 Lorimer PD, Motz BM, Watson M, Trufan SJ, Prabhu RS, Hill JS, Salo JC (2019) Enteral feeding
access has an impact on outcomes for patients with esophageal cancer undergoing
esophagectomy: an analysis of SEER-medicare. Ann Surg Oncol 26:1311–1319 Mahmoodzadeh H, Shoar S, Sirati F, Khorgami Z (2015) Early initiation of oral feeding following
upper gastrointestinal tumor surgery: a randomized controlled trial. Surg Today 45:203–208 Malhotra GK, Yanala U, Ravipati A, Follet M, Vijayakumar M, Are C (2017) Global trends in
esophageal cancer. J Surg Oncol 115:564–579 Martin L, Lagergren P (2009) Long-term weight change after oesophageal cancer surgery. Br J Surg
96:1308–1314 Miyazaki T, Tanaka N, Hirai H, Yokobori T, Sano A, Sakai M, Inose T, Sohda M, Nakajima M,
Fukuchi M, Kato H, Kuwano H (2012) Ghrelin level and body weight loss after esophagectomy
for esophageal cancer. J Surg Res 176:74–78 Murphy C (2020) Personalising the approach to unintentional weight loss after oesophagectomy by
exploring the role of gut-brain signalling. University College Dublin, Dublin Murphy CF, Stratford N, Docherty NG, Moran B, Elliott JA, Healy ML, Mcmorrow JP, Ravi N,
Goldstone AP, Reynolds JV, Le Roux CW (2021) A pilot study of gut-brain signaling after
octreotide therapy for unintentional weight loss after esophagectomy. J Clin Endocrinol Metab
106:e204–e216 Myronovych A, Kirby M, Ryan KK, Zhang W, Jha P, Setchell KD, Dexheimer PJ, Aronow B,
Seeley RJ, Kohli R (2014) Vertical sleeve gastrectomy reduces hepatic steatosis while increas-
ing serum bile acids in a weight-loss-independent manner. Obesity (Silver Spring) 22:390–400 Ouattara M, D’Journo XB, Loundou A, Trousse D, Dahan L, Doddoli C, Seitz JF, Thomas PA
(2012) Body mass index kinetics and risk factors of malnutrition one year after radical
oesophagectomy for cancer. Eur J Cardiothorac Surg 41:1088–1093 Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK, Maratos-Flier E,
Mun EC, Pihlajamaki J, Auwerx J, Goldfine AB (2009) Serum bile acids are higher in humans
with prior gastric bypass: potential contribution to improved glucose and lipid metabolism.
Obesity (Silver Spring) 17:1671–1677 Pournaras DJ, Glicksman C, Vincent RP, Kuganolipava S, Alaghband-Zadeh J, Mahon D, Bekker
JH, Ghatei MA, Bloom SR, Walters JR, Welbourn R, Le Roux CW (2012) The role of bile after
Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocri-
nology 153:3613–3619 Pournaras DJ, Hardwick RH, Le Roux CW (2017) Gastrointestinal surgery for obesity and cancer:
2 sides of the same coin. Surg Obes Relat Dis 13:720–721 Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P (2017) Cancer of the esophagus
and esophagogastric junction: an eighth edition staging primer. J Thorac Oncol 12:36–42 Ryan AM, Rowley SP, Healy LA, Flood PM, Ravi N, Reynolds JV (2006) Post-oesophagectomy
early enteral nutrition via a needle catheter jejunostomy: 8-year experience at a specialist unit.
Clin Nutr 25:386–393 Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R,
Wilson-Pérez HE, Sandoval DA, Kohli R, Bäckhed F, Seeley RJ (2014) FXR is a molecular
target for the effects of vertical sleeve gastrectomy. Nature 509:183–188 Scarpellini E, Arts J, Karamanolis G, Laurenius A, Siquini W, Suzuki H, Ukleja A, Van Beek A,
Vanuytsel T, Bor S, Ceppa E, Di Lorenzo C, Emous M, Hammer H, Hellström P, Laville M,
Lundell L, Masclee A, Ritz P, Tack J (2020) International consensus on the diagnosis and
management of dumping syndrome. Nat Rev Endocrinol 16:448–466
324 A. Sudlow et al.
https://t.me/med1917
Schandl A, Kauppila JH, Anandavadivelan P, Johar A, Lagergren P (2019) Predicting the risk of
weight loss after esophageal cancer surgery. Ann Surg Oncol 26:2385–2391 Schandl A, Johar A, Anandavadivelan P, Vikström K, Mälberg K, Lagergren P (2020) Patient-
reported outcomes 1 year after oesophageal cancer surgery. Acta Oncol 59:613–619 Shapiro J, Van Lanschot JJB, Hulshof MCCM, Van Hagen P, Van Berge Henegouwen MI,
Wijnhoven BPL, Van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp
JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker
JTM, Verheul HMW, Bilgen EJS, Van Dekken H, Van Der Sangen MJC, Rozema T,
Biermann K, Beukema JC, Piet AHM, Van Rij CM, Reinders JG, Tilanus HW, Steyerberg
EW, Van Der Gaast A, Group CS (2015) Neoadjuvant chemoradiotherapy plus surgery versus
surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised
controlled trial. Lancet Oncol 16:1090–1098 Shemmeri E, Fabian T (2021) Staging of esophageal malignancy. Surg Clin North Am
101:405–414 Soriano TT, Eslick GD, Vanniasinkam T (2018) Long-term nutritional outcome and health related
quality of life of patients following Esophageal cancer surgery: a meta-analysis. Nutr Cancer
70:192–203 Spreckley E, Murphy KG (2015) The L-cell in nutritional sensing and the regulation of appetite.
Front Nutr 2:23 Steenhagen E (2019) Preoperative nutritional optimization of esophageal cancer patients. J Thorac
Dis 11:S645–S653 Sun HB, Li Y, Liu XB, Zhang RX, Wang ZF, Lerut T, Liu CC, Fiorelli A, Chao YK, Molena D,
Cerfolio RJ, Ozawa S, Chang AC, Group WOBOTATSC (2018) Early oral feeding following
McKeown minimally invasive esophagectomy: an open-label, randomized, controlled,
noninferiority trial. Ann Surg 267:435–442 Tack J, Arts J, Caenepeel P, De Wulf D, Bisschops R (2009) Pathophysiology, diagnosis and
management of postoperative dumping syndrome. Nat Rev Gastroenterol Hepatol 6:583–590 Tham JC, Dovell G, Berrisford RG, Humphreys ML, Wheatley TJ, Sanders G, Ariyarathenam AV
(2020) Routine use of feeding jejunostomy in oesophageal cancer resections: results of a survey
in England. Dis Esophagus 33 The Royal College of Surgeons of England (David Cromwell, Hussein Wahedally, Min Hae Park),
The Association of Upper GI Surgeons (Nick Maynard), The Royal College of Radiologists
(Tom Crosby), The British Society of Gastroenterologists (Nigel Trudgill), NHS Digital (Jane
Gaskill, Rose Napper) (2019) National Oesophago-gastric Cancer Audit. 11th edn Tremaroli V, Karlsson F, Werling M, Stahlman M, Kovatcheva-Datchary P, Olbers T, Fandriks L,
Le Roux CW, Nielsen J, Backhed F (2015) Roux-en-Y gastric bypass and vertical banded
gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass
regulation. Cell Metab 22:228–238 Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath
MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR (1996) A role for
glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69–72 Wainwright D, Donovan JL, Kavadas V, Cramer H, Blazeby JM (2007) Remapping the body:
learning to eat again after surgery for esophageal cancer. Qual Health Res 17:759–771 Weijs TJ, Berkelmans GH, Nieuwenhuijzen GA, Dolmans AC, Kouwenhoven EA, Rosman C,
Ruurda JP, Van Workum F, Van Det MJ, Silva Corten LC, Van Hillegersberg R, Luyer MD
(2016) Immediate postoperative oral nutrition following esophagectomy: a multicenter clinical
trial. Ann Thorac Surg 102:1141–1148 Weijs TJ, Van Eden HWJ, Ruurda JP, Luyer MDP, Steenhagen E, Nieuwenhuijzen GAP, Van
Hillegersberg R (2017) Routine jejunostomy tube feeding following esophagectomy. J Thorac
Dis 9:S851–S860 Wheeler JB, Reed CE (2012) Epidemiology of esophageal cancer. Surg Clin North Am
92:1077–1087
Unintentional Weight Loss and Malnutrition After Esophageal Cancer and Treatment 325
https://t.me/med1917
Wouters MW, Karim-Kos HE, Le Cessie S, Wijnhoven BP, Stassen LP, Steup WH, Tilanus HW,
Tollenaar RA (2009) Centralization of esophageal cancer surgery: does it improve clinical
outcome? Ann Surg Oncol 16:1789–1798 Yamamoto K, Takiguchi S, Miyata H, Miyazaki Y, Hiura Y, Yamasaki M, Nakajima K,
Fujiwara Y, Mori M, Kangawa K, Doki Y (2013) Reduced plasma ghrelin levels on day
1 after esophagectomy: a new predictor of prolonged systemic inflammatory response syn-
drome. Surg Today 43:48–54 Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L,
Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P (2011) Perioperative chemotherapy
compared with surgery alone for resectable gastroesophageal adenocarcinoma:an FNCLCC and
FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721 Zhang H, Dibaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, Parameswaran P, Crowell MD,
Wing R, Rittmann BE, Krajmalnik-Brown R (2009) Human gut microbiota in obesity and after
gastric bypass. Proc Natl Acad Sci U S A 106:2365–2370
Current Clinical Landscape
https://t.me/med1917
of Immunotherapeutic Approaches in Pancreatic Cancer Treatment
Pooya Farhangnia
, Shamim Mollazadeh Ghomi
,
Shabnam Mollazadehghomi, and Ali-Akbar Delbandi
Abstract
As a significant contributor to cancer-related death, pancreatic cancer, as a
recalcitrant tum or, generally has an appalling prognosis that has not altered
over many years. At the moment, prevention or early identification at a stage
where treatment is still possible is exceptionally challenging because patients
seldom show symptoms, and tumors exhibit no sensitive and specific indicators to
help with detection. Most patients have advanced or metastatic, intricate malig-
nancy, and standard of care treatments, such as chemotherapy and radiothera py,
may extend life by several months in these cases. The approach to treating
pancreatic cancer has been fundamentally revolutionized due to immunotherapy.
However, the immunosuppressive, inaccessible tumor microenvironment (TME)
may be the reason for its low immunotherapeutic effectiveness in pancreatic
cancer. In this chapter, we address pancreatic cancer immunosuppressive TME
P. Farhangnia Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Chicago, IL, USA e-mail: Farhangnia.po@iums.ac.ir
S. Mollazadeh Ghomi · S. Mollazadehghomi Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Chicago, IL, USA
A.-A. Delbandi ( Reproductive Sciences and Technology Research Center, Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Chicago, IL, USA e-mail: Delbandi.ak@Iums.ac.ir
✉)
#
The Author(s), under exclusive license to Springer Nature Switzerland AG 2023 Interdisciplinary Cancer Research, https://doi.org/10.1007/16833_2023_163 Published online: 29 June 2023
327
328 P. Farhangnia et al.
https://t.me/med1917
and underscore an extensive spectrum of immunotherapies, including oncolytic virus therapy, adoptive cell transfer therapy (i.e., T-cell receptor [TCR]­engineered T cells therapy, chimeric antigen receptor [CAR] T-cell therapy, CAR natural killer [NK] cell therapy, and cytokine-induced killer cells), immune checkpoints blockade and immunomodulators, cancer vaccines, and immunother­apeutic strategies based on targeting myeloid cells.
Keywords
Cancer immunotherapy · CAR NK cell therapy · CAR T-cell therapy · Immune checkpoint blockade · Immunotherapy · Oncolytic virus therapy · Pancreatic cancer
Abbreviations
APC Antigen-presenting cell ATRA All-trans retinoic acid BM Bone marrow CAF Cancer-associa ted fibroblast CAR Chimeric antigen receptor cDC1 Type 1 conventional dendritic cell CEA Carcinoembryonic antigen CIK Cytokine-induced killer CSF1R Colony-stimulating factor 1 receptor CTL Cytotoxic T lymphocyte CTLA-4 Cytotoxic T lymphocyte antigen-4 DC Dendritic cell ECM Extracellular matrix EGFR Epidermal growth factor receptor ENO1 α-Enolase EpCAM Epithelial cell adhesion molecule FAPα Fibroblast activation protein alpha FDA US Food and Drug Administration GATA-3 GATA binding protein 3 G-CSF Granulocyte colony-stimulating factor GM-CSF Granulocyte-macrophage colony-stimulating factor HER2 Human epidermal growth factor receptor 2 HIF Hypoxia-inducible factor HMGB1 High mobility group box 1 protein HSV Herpes simplex virus ICB Immune checkpoint blockade IDO Indoleamine 2, 3-dioxygenase IFN-γ Interferon-gamma IL Interleukin